Bi Chao, Han Fang-Ju, Ding Gang, Shi Ye-Qiang
Department of Ophthalmology, Jinan Second People's Hospital Jinan 250000, Shandong, China.
Am J Transl Res. 2025 Aug 15;17(8):6434-6441. doi: 10.62347/KRVZ8121. eCollection 2025.
To evaluate the impact of Compound Tropicamide (Trop) Eye Drops on the visual quality in juvenile pseudomyopia patients.
Data from 111 juvenile pseudomyopia patients treated between September 2019 and September 2022 were reviewed in this retrospective study, including 50 cases treated with Atropine Sulfate Ophthalmic Gel (control group) and 61 with Compound Trop Eye Drops (research group). Clinical efficacy, amplitude of accommodation (AA), uncorrected visual acuity (UCVA), intraocular pressure (IOP), axial length (AL), symptom improvement, complications, and quality of life were compared. Risk factors for visual quality improvement were analyzed using Logistic regression.
The research group demonstrated significantly higher treatment efficacy compared to the control group (P>0.05). Post-treatment, AA, IOP, and AL decreased notably in the research group compared to baseline and the control group (all P<0.05). UCVA and quality of life scores improved significantly in the research group (both P<0.05). Recovery indicators, including resolution of dizziness, alleviation of ocular soreness, and vision recovery, were significantly shorter in the research group (all P<0.05). Both groups had similar complication rates, including dry mouth, facial blushing, conjunctival congestion, and transient tachycardia (P>0.05). The research group reported superior post-treatment quality of life across all domains (all P<0.05). Logistic regression showed that gender, age, disease duration, family history of myopia, education level, AA, UCVA, and treatment method were not significant risk factors for visual quality improvement (all P>0.05).
Compound Trop Eye Drops effectively enhances visual function and quality of life in juvenile pseudomyopia patients, with a safety profile comparable to low-dose atropine, offering potential clinical value.
评估复方托吡卡胺滴眼液对青少年假性近视患者视觉质量的影响。
本回顾性研究回顾了2019年9月至2022年9月期间治疗的111例青少年假性近视患者的数据，其中50例使用硫酸阿托品眼用凝胶治疗（对照组），61例使用复方托吡卡胺滴眼液治疗（研究组）。比较临床疗效、调节幅度（AA）、裸眼视力（UCVA）、眼压（IOP）、眼轴长度（AL）、症状改善情况、并发症及生活质量。采用Logistic回归分析视觉质量改善的危险因素。
研究组的治疗效果显著高于对照组（P>0.05）。治疗后，研究组的AA、IOP和AL较基线和对照组均显著降低（均P<0.05）。研究组的UCVA和生活质量评分显著提高（均P<0.05）。研究组头晕缓解、眼痛减轻和视力恢复等恢复指标明显缩短（均P<0.05）。两组的并发症发生率相似，包括口干、面部潮红、结膜充血和短暂性心动过速（P>0.05）。研究组在所有领域的治疗后生活质量均较高（均P<0.05）。Logistic回归显示，性别、年龄、病程、近视家族史、教育程度、AA、UCVA和治疗方法不是视觉质量改善的显著危险因素（均P>0.05）。
复方托吡卡胺滴眼液可有效提高青少年假性近视患者的视觉功能和生活质量，安全性与低剂量阿托品相当，具有潜在的临床价值。
